MA39963A - Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin - Google Patents

Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin

Info

Publication number
MA39963A
MA39963A MA039963A MA39963A MA39963A MA 39963 A MA39963 A MA 39963A MA 039963 A MA039963 A MA 039963A MA 39963 A MA39963 A MA 39963A MA 39963 A MA39963 A MA 39963A
Authority
MA
Morocco
Prior art keywords
methods
ibd
smad7
subject
disclosed
Prior art date
Application number
MA039963A
Other languages
English (en)
Inventor
Giovanni Monteleone
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MA39963A publication Critical patent/MA39963A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des méthodes de traitement d'un sujet atteint d'une maladie inflammatoire chronique de l'intestin (mici) faisant appel à une thérapie anti-smad7, par exemple à l'aide d'un oligonucléotide antisens smad7, de manière à réduire les niveaux de crp. L'invention concerne des méthodes de traitement et de prise en charge d'une mici chez un sujet à l'aide d'une thérapie anti-smad7, par exemple faisant appel à un oligonucléotide antisens smad7, sur la base des niveaux de crp. L'invention concerne également des procédés permettant de déterminer si un sujet atteint d'une mici répond, ou est susceptible de répondre, à un traitement consistant en une thérapie anti-smad7. La réduction des niveaux de crp peut être corrélée à une rémission de la mici ou à une baisse du score d'activité clinique. La présente invention concerne également le traitement d'une mici à l'aide d'une thérapie anti-smad7 (par exemple faisant appel à un oligonucléotide antisens) en combinaison avec un agent supplémentaire. L'invention concerne également des compositions pharmaceutiques et des nécessaires associés.
MA039963A 2014-05-09 2015-05-08 Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin MA39963A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461991326P 2014-05-09 2014-05-09
US201462065609P 2014-10-17 2014-10-17
US201462065606P 2014-10-17 2014-10-17

Publications (1)

Publication Number Publication Date
MA39963A true MA39963A (fr) 2017-03-15

Family

ID=53059121

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039963A MA39963A (fr) 2014-05-09 2015-05-08 Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin

Country Status (11)

Country Link
US (1) US10473669B2 (fr)
EP (1) EP3140658A2 (fr)
JP (1) JP2017515896A (fr)
KR (1) KR20170005058A (fr)
CN (1) CN106573065A (fr)
AU (1) AU2015257589A1 (fr)
CA (1) CA2948411A1 (fr)
MA (1) MA39963A (fr)
MX (1) MX2016014624A (fr)
RU (1) RU2016147569A (fr)
WO (1) WO2015169966A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
CA2743329C (fr) 2008-11-13 2020-09-01 Giuliani International Limited Compositions antisens et procedes de preparation et d'utilisation de celles-ci
CN104040349B (zh) 2011-09-15 2017-07-04 诺格尔制药有限公司 用于监测对抗smad7疗法的反应性的方法
WO2013158868A1 (fr) 2012-04-18 2013-10-24 Nogra Pharma Limited Procédés pour traiter le diabète et/ou favoriser la survie d'îlots pancréatiques après une transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
MX2016014624A (es) 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
AU2015332624A1 (en) 2014-10-17 2017-05-04 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
WO2017147276A1 (fr) * 2016-02-23 2017-08-31 Celgene Corporation Méthodes de traitement de la fibrose intestinale par inhibition de smad7
WO2017144689A1 (fr) * 2016-02-24 2017-08-31 Nogra Pharma Limited Procédés de traitement de la maladie cœliaque en inhibant smad7
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
CA3047302C (fr) * 2016-12-14 2024-01-02 Tracy WARREN Systeme et procedes de developpement et d'utilisation d'un composant d'action a base de microbiome pour la sante d'un patient
JP2020528910A (ja) * 2017-07-28 2020-10-01 セルジーン コーポレイション オリゴヌクレオチド化合物の調製方法
WO2021034727A1 (fr) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations et production et purification d'interleukines
WO2021214548A2 (fr) * 2020-04-24 2021-10-28 Nogra Pharma Limited Compositions d'oligonucléotides antisens (aso) smad7 et leurs procédés d'utilisation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257932A1 (en) * 1997-02-28 2006-11-16 Yaron Ilan Treatment of Crohn's disease
PT1456380E (pt) 2001-11-02 2012-07-23 Giuliani Int Ltd Inibidores smad7 para o tratamento de doenças do snc
AU2003213231A1 (en) * 2002-02-25 2003-09-09 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20050118655A1 (en) * 2003-11-17 2005-06-02 University Of Iowa Research Foundation Use of parasitic biological agents for diseases prevention and control
CA2743329C (fr) 2008-11-13 2020-09-01 Giuliani International Limited Compositions antisens et procedes de preparation et d'utilisation de celles-ci
EP2488659B1 (fr) * 2009-10-15 2019-12-11 Crescendo Bioscience, Inc. Biomarqueurs et procédés de mesure et de surveillance de l'activité d'une maladie inflammatoire
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CA2839792A1 (fr) * 2011-05-10 2012-11-15 Nestec S.A. Methodes de profilage de l'activite d'une maladie pour une prise en charge therapeutique personnalisee
CN104040349B (zh) * 2011-09-15 2017-07-04 诺格尔制药有限公司 用于监测对抗smad7疗法的反应性的方法
WO2013158868A1 (fr) 2012-04-18 2013-10-24 Nogra Pharma Limited Procédés pour traiter le diabète et/ou favoriser la survie d'îlots pancréatiques après une transplantation
EP2849565A4 (fr) * 2012-05-19 2016-03-23 Falk Pharma Gmbh Compositions et méthodes, faisant appel au 5-aminosalicylate, pouvant être utilisées en vue du traitement du syndrome du côlon irritable
US9772334B2 (en) * 2012-12-10 2017-09-26 The Regents Of The University Of California Inflammatory bowel disease markers and therapies for colitis-associated intestinal fibrosis
CA2903597C (fr) 2013-03-15 2023-04-04 Nogra Pharma Limited Methodes de traitement du cancer colorectal
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP3004892B1 (fr) * 2013-05-24 2018-10-10 Nestec S.A. Methode pour le diagnostic du syndrome du côlon irritable
MX2016014624A (es) 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
US20170233736A1 (en) * 2014-10-17 2017-08-17 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
AU2015332624A1 (en) 2014-10-17 2017-05-04 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
JP2018531936A (ja) 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法
WO2017144689A1 (fr) 2016-02-24 2017-08-31 Nogra Pharma Limited Procédés de traitement de la maladie cœliaque en inhibant smad7
WO2018122376A1 (fr) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions d'oligonucléotide antisens de protéine smad7 et méthodes de traitement ou de prévention du psoriasis

Also Published As

Publication number Publication date
CA2948411A1 (fr) 2015-11-12
CN106573065A (zh) 2017-04-19
KR20170005058A (ko) 2017-01-11
RU2016147569A3 (fr) 2018-12-28
EP3140658A2 (fr) 2017-03-15
WO2015169966A3 (fr) 2016-02-04
US10473669B2 (en) 2019-11-12
WO2015169966A2 (fr) 2015-11-12
MX2016014624A (es) 2017-05-25
RU2016147569A (ru) 2018-06-13
JP2017515896A (ja) 2017-06-15
AU2015257589A1 (en) 2016-11-24
US20180180630A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MA39963A (fr) Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA201790398A1 (ru) Способы лечения заболевания печени
WO2016059243A3 (fr) Procédés de dosage et de suivi d'un traitement avec un oligonucléotide antisens de smad7 utilisant des teneurs en marqueurs biologiques
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
NZ707035A (en) Gene signatures of inflammatory disorders that relate to the liver
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MY192605A (en) Compositions and methods for inhibiting arginase activity
EA201891501A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
EA201790802A1 (ru) Соединения против tnf
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
NZ738100A (en) Igfbp3 and uses thereof
MX2019000221A (es) Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma.
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2016017097A (es) Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2).
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
EP3581653A3 (fr) Procédés et compositions pour le traitement du cancer au moyen d'agents à base d'acides nucléiques de peptides